Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0182)
| Name |
Trolox
|
||||
|---|---|---|---|---|---|
| Synonyms |
trolox; 53188-07-1; 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; TROLOX C; 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; 56305-04-5; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-; CHEBI:82625; S18UL9710X; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid; (+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; EINECS 258-422-8; MFCD00006846; BRN 5052542; UNII-S18UL9710X; Trolox(TM); Prestwick_855; TROLOX [INCI]; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; Prestwick0_000530; Prestwick1_000530; Prestwick2_000530; Prestwick3_000530; TROLOX [MI]; CHEMBL153; SCHEMBL3226; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, (+-)-; Oprea1_727377; BSPBio_000519; MLS002153860; SPBio_002440; (+/-)-TROLOX; BPBio1_000571; 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; DTXSID60866306; HMS1569J21; HMS2096J21; HMS2230A15; HMS3369E20; HMS3713J21; HMS3885K19; (R,S)-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid; BCP16474; BBL103047; BDBM50359629; GEO-03688; s3665; STL556856; AKOS015856256; CCG-207912; CS-8035; 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2- carboxylic acid; NCGC00179534-01; AS-30121; SMR001233218; HY-101445; FT-0621156; FT-0770514; H0726; EN300-370592; Q245489; SR-01000841227; SR-01000841227-2; BRD-A17846016-001-03-0; BRD-A17846016-001-07-1; 6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromancarboxylic acid; Z3013814504; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid #; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)carboxylic acid; (+/-)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%; (S)-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLICACID; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID, (+/-)-; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic Acid;; 6-hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; Trolox is also know as 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.; 2H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-, (+/-)-
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C14H18O4
|
||||
| IUPAC Name |
6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid
|
||||
| Canonical SMILES |
CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C
|
||||
| InChI |
InChI=1S/C14H18O4/c1-7-8(2)12-10(9(3)11(7)15)5-6-14(4,18-12)13(16)17/h15H,5-6H2,1-4H3,(H,16,17)
|
||||
| InChIKey |
GLEVLJDDWXEYCO-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Head neck squamous cell carcinoma | ICD-11: 2D60 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | LICR-HN2 R10.3 cells | Laryngeal squamous cell carcinoma | Homo sapiens | CVCL_LI54 |
| SNU-1 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0099 | |
| Response regulation | Artesunate induced ferroptosis in head and neck cancer (HNC) cells by decreasing cellular GSH levels and increasing lipid ROS levels. This effect was blocked by co-incubation with ferrostatin-1 and a trolox pretreatment. Artesunate activated the Nrf2-antioxidant response element (ARE) pathway in HNC cells, which contributed to ferroptosis resistance. | |||